| Breast Carcinoma
Zoladex vs Enhertu
Side-by-side clinical, coverage, and cost comparison for breast carcinoma.Deep comparison between: Zoladex vs Enhertu with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEnhertu has a higher rate of injection site reactions vs Zoladex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Enhertu but not Zoladex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zoladex
Enhertu
At A Glance
SC injection
Every 28 days
GnRH agonist
IV infusion
Every 3 weeks
HER2-directed antibody-drug conjugate with topoisomerase I inhibitor
Indications
- Prostate carcinoma
- Endometriosis
- Abnormal uterine bleeding
- Breast Carcinoma
- Breast Carcinoma
- Non-Small Cell Lung Carcinoma
- Gastric Adenocarcinoma
Dosing
Prostate carcinoma (Stage B2-C) 3.6 mg SC every 28 days starting 8 weeks before radiotherapy, in combination with flutamide, continued during radiation therapy; alternatively, a 10.8 mg depot may follow the initial 3.6 mg depot.
Prostate carcinoma (advanced) 3.6 mg SC every 28 days; intended for long-term administration.
Endometriosis 3.6 mg SC every 28 days for 6 months.
Abnormal uterine bleeding One or two 3.6 mg SC depots given 4 weeks apart; surgery performed at 4 weeks after one depot, or within 2-4 weeks after the second depot.
Breast Carcinoma 3.6 mg SC every 28 days; intended for long-term administration.
Breast Carcinoma (HER2-positive, HER2-low, or HER2-ultralow) 5.4 mg/kg IV infusion every 3 weeks until disease progression or unacceptable toxicity
Breast Carcinoma (HER2-positive, first-line with pertuzumab) Cycle 1 Day 1: 5.4 mg/kg IV followed by pertuzumab 840 mg; subsequent cycles: 5.4 mg/kg IV followed by pertuzumab 420 mg every 3 weeks
Non-Small Cell Lung Carcinoma (HER2-mutant) 5.4 mg/kg IV infusion every 3 weeks until disease progression or unacceptable toxicity
Gastric Adenocarcinoma (HER2-positive) 6.4 mg/kg IV infusion every 3 weeks until disease progression or unacceptable toxicity
Contraindications
- Known hypersensitivity to GnRH, GnRH agonist analogues, or any component of ZOLADEX
- Pregnancy (except when used for palliative treatment of advanced breast cancer)
—
Adverse Reactions
Most common (>10%) in men Hot flashes, sexual dysfunction, decreased erections, lower urinary tract symptoms
Most common (>20%) in women Hot flushes, headache, sweating, acne, emotional lability, depression, decreased libido, vaginitis, breast atrophy, seborrhea, peripheral edema
Serious Tumor flare, ureteral obstruction, spinal cord compression, pituitary apoplexy
Postmarketing Osteoporosis, bone fracture, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, transient ischemic attack, ovarian cyst, pituitary adenoma, SJS/TEN, DRESS, AGEP, erythema multiforme, psychotic disorders, suicidal ideation, convulsions
Most common (>=20%) Decreased white blood cell count, nausea, decreased hemoglobin, decreased neutrophil count, decreased lymphocyte count, fatigue, decreased platelet count, increased aspartate aminotransferase, increased alanine aminotransferase, increased blood alkaline phosphatase, vomiting, alopecia, decreased blood potassium, constipation, musculoskeletal pain, diarrhea, decreased appetite
Serious Interstitial lung disease, pneumonitis, pneumonia, febrile neutropenia, vomiting, nausea, hypokalemia, pulmonary embolism, sepsis
Pharmacology
ZOLADEX is a synthetic decapeptide analogue of GnRH that inhibits pituitary gonadotropin secretion; chronic administration suppresses serum testosterone in males to castrate levels and reduces serum estradiol in females to postmenopausal levels, leading to regression of hormone-sensitive tumors and accessory sex organ regression.
Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate consisting of a humanized anti-HER2 IgG1 antibody linked to a topoisomerase I inhibitor (DXd). After binding to HER2 on tumor cells, the drug undergoes internalization and lysosomal cleavage, releasing the membrane-permeable DXd that causes DNA damage and apoptotic cell death.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zoladex
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Enhertu
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Zoladex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Enhertu
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Zoladex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Enhertu
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Zoladex.
No savings programs available for Enhertu.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZoladexView full Zoladex profile
EnhertuView full Enhertu profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.